Clinical study of cryoablation combined with immune checkpoint inhibitors in the treatment of solid tumors

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050931

Enrollment

Unknown

Registered

2021-09-08

Start date

2021-09-30

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

Control group:cryoablation

Experimental group:cryoablation + PD-1 monoclonal antibody therapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 and 70 x 10^9. 5. ECOG score 0-1 points. 6. The pathological result is hepatocellular carcinoma (HCC) or one of the four examinations including contrast-enhanced ultrasound, dynamic contrast-enhanced CT, Gd-DTPA dynamic-enhanced MRI and Gd-EOB-DTPA dynamic-enhanced MRI has typical liver cancer characteristics. 7. Understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding patients; 2. Patients with autoimmune diseases, organ/hematopoietic stem cell transplantation or other malignant tumors; 3. Patients with impaired consciousness or unable to cooperate with treatment, and patients with mental illness; 4. Patients who have participated in other clinical trials in the past three months; 5. Huge tumor, or diffuse liver cancer; 6. The liver function classification is Child-Pugh C, which cannot be improved by liver protection treatment; 7. Bleeding from esophageal (stomach fundus) varices within 1 month before treatment; 8. Uncorrectable coagulation dysfunction and severe blood abnormalities, with severe bleeding tendency. Severe coagulation abnormality cannot withstand surgery (anticoagulation therapy and/or anticoagulant drug application should be discontinued for more than 1 week before ablation therapy); 9. Intractable massive ascites, cachexia; 10. Active infection, especially inflammation of the biliary system; 11. Severe liver, kidney, heart, lung, brain and other major organ failure.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;Blood routine;Hepatic function;Renal function;Coagulation function;Alpha-fetoprotein;Carbohydrate antigen;Electrocardiogram;Enhanced MRI of liver;	—

Secondary

Measure	Time frame
Overall survival;Time to progression;Objective response rate;Adverse reactions;Adverse events;	—

Countries

China

Contacts

Public ContactZhou Xiang

Chinese Academy of Medical Sciences Cancer Hospital

zhou.xiang@yeah.net+86 18910612829

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026